VMI
RLMD icon

VHCP Management III’s Relmada Therapeutics RLMD Stock Holding History

VHCP Management III’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$29.9M Buy
+767,938
New +$23.3M 5.95% 4

Other funds holding RLMD

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
TA
Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

VHCP Management III's RLMD Position: Q4 2019 in Review

VHCP Management III opened a new position in Relmada Therapeutics (RLMD) in Q4 2019: 767,938 shares worth $29.9M. The stake represents 5.95% of the portfolio and ranks #4 among its holdings.

45 funds tracked by Wall St. Rank hold RLMD as of Q4 2019.

  • VHCP Management III held 767,938 shares of Relmada Therapeutics worth $29.9M as of Q4 2019.
  • Relmada Therapeutics was a new VHCP Management III position in Q4 2019.
  • Relmada Therapeutics made up 5.95% of VHCP Management III's portfolio in Q4 2019, its #4 holding.
  • 45 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2019.

Based on VHCP Management III's 13F filing for Q4 2019, filed 13 Feb 2020.